Vascular pharmacotherapy and dementia.
The incidence of dementia is increasing dramatically with the ageing population. Increasing evidence indicates that vascular disease is associated with cognitive decline and with the most common form of dementia, Alzheimer's disease (AD). Cardiovascular risk factors such as hyperlipidaemia, hypertension and type 2 diabetes have attracted attention as potential targets in the prevention of dementia. The present review aims to provide a concise overview of the recent advances linking vascular disease with dementia (with a particular focus on AD) and to examine the evidence for efficacy, where possible, for utilising vascular pharmacotherapy as a treatment option for dementia.
Piguet
Olivier
O
Prince of Wales Medical Research Institute, Randwick NSW 2031, Australia.
Garner
Brett
B
D000544:Alzheimer Disease / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000924:Anticholesteremic Agents / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D050197:Atherosclerosis / Q000150:complications / Q000503:physiopathology / Q000517:prevention & control; D003704:Dementia / Q000209:etiology / Q000503:physiopathology* / Q000517:prevention & control*; D019587:Dietary Supplements; D015525:Fatty Acids, Omega-3 / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D047495:PPAR gamma / Q000819:agonists; D012307:Risk Factors; D014652:Vascular Diseases / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology* / Q000517:prevention & control; D014815:Vitamins / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D000924:Anticholesteremic Agents; D000959:Antihypertensive Agents; D015525:Fatty Acids, Omega-3; D007004:Hypoglycemic Agents; D007328:Insulin; D047495:PPAR gamma; D014815:Vitamins